Angioimmunoblastic T-Cell Lymphoma
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
TET2,
IDH2,
RHOA,
DNMT3A,
NOS2,
MME,
NOS1,
BCL6,
ALK,
CXCL13,
IDH1,
VEGFA,
CD28,
IGH,
TRBV20OR9-2,
ICOS,
PDGFRA,
FBL,
ITK,
PLCG1,
TP53,
SYK,
TNFRSF8,
CR2,
CRP,
BCL2,
IL21,
TARP,
CYGB,
PDLIM7
TET2,
IDH2,
RHOA,
DNMT3A,
NOS2,
MME,
NOS1,
BCL6,
ALK,
CXCL13,
IDH1,
VEGFA,
CD28,
IGH,
TRBV20OR9-2,
ICOS,
PDGFRA,
FBL,
ITK,
PLCG1,
TP53,
SYK,
TNFRSF8,
CR2,
CRP,
BCL2,
IL21,
TARP,
CYGB,
PDLIM7,
RC3H1,
MIR146A,
TCL1A,
ZAP70,
PWWP3A,
MIR193B,
VAV1,
MIR664A,
LOC102723407,
TNF,
TEK,
TRGC1,
TRG,
CD163,
SIRT1,
DUSP22,
TBX21,
ALLC,
AHI1,
SAMSN1,
RTEL1,
NCKIPSD,
LEF1,
IL22,
CMIP,
SMUG1,
PYCARD,
IGHV3-69-1,
IGHV3OR16-7,
TNFRSF21,
FIP1L1,
ACAD8,
NOCT,
ACVRL1,
PIK3CB,
TCF7,
SPN,
GATA3,
GAPDH,
FYN,
MTOR,
FOXO1,
FCGRT,
EZH2,
ELAVL2,
DLAT,
CTNNB1,
CCR4,
CD68,
ENTPD1,
CCND3,
BRAF,
CXCR5,
STS,
ANGPT2,
ANGPT1,
CXCR3,
GTF2I,
HDAC1,
KDR,
SLPI,
SRSF2,
RAG2,
RAG1,
PIK3CG,
PIK3CD,
PIK3CA,
PDCD1,
IRF4,
HDAC2,
IL10,
CXCL8,
IL6,
IL5,
IL4,
IFNG,
HLA-G,
HGF,
LOC102724971
Drugs
Alisertib,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Belinostat
(
BELEODAQ
)
Alisertib,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Belinostat
(
BELEODAQ
),
Brentuximab vedotin
(
ADCETRIS
),
Darinaparsin,
Fenretinide,
Iodine (131I) tositumomab,
Mogamulizumab
(
POTELIGEO
),
N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide,
Pralatrexate
(
FOLOTYN
),
Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,
Romidepsin
(
ISTODAX
),
Siplizumab,
Zanolimumab,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
A rare T-cell non-Hodgkin lymphoma characterized by infiltration of lymph nodes by neoplastic cells of T follicular helper cell origin with a polymorphous inflammatory background including markedly increased follicular dendritic cells and EBV-positive B-cells, as well as prominent proliferation of high endothelial venules. The spleen, liver, skin, and bone marrow are also frequently involved. Patients typically present with generalized lymphadenopathy, hepatosplenomegaly, systemic symptoms, and polyclonal hypergammaglobulinemia. Pruritic skin rash, arthritis, pleural effusion, and ascites may also be observed. The condition is aggressive with generally poor prognosis.